That the stem cell model has clinical significance in AML is suggested by studies such as one which showed that the percentage of CD34+CD38- LSCs at the time of diagnosis correlated with the duration of relapse-free survival in 92 patients (van Rhenen et al., 2005). This evidence concerns the gene CD34 and acute myeloid leukemia.